MDACC Study No:BTTC08-01-MDA ( NCT No: NCT00720356)
Title:A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation
Principal Investigator:John DeGroot
Treatment Agent:Bevacizumab; Erlotinib; Temozolomide
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
bevacizumab and erlotinib after treatment with temozolomide and radiation
therapy will help to control glioblastoma when a certain gene called MGMT is
turned "on". The safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Brain Tumor Trials Collaborative(BTTC)
Return Visit:Every 2 weeks
Home Care:Patients will take temozolomide and erlotinib at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults